A clinical case of a patient with recurrent bladder cancer and primary multiple metachronous tumors
https://doi.org/10.17650/2782-3202-2024-4-4-94-99
Abstract
In the clinical practice of an oncologist, primary multiple tumors are one of the most difficult and poorly understood problems. The treatment of patients with multiple malignancies often involves а combined treatment methods. Taking into account the possibility of detecting tumors at different stages and localizations, the doctor needs to determine such a therapeutic approach that will be directed at several oncological processes at once. The article describes a clinical case of a male patient, born in 1948, with metachronous bladder cancer, both lungs and multifocal basal cell skin cancer.
The presented experience reflects the patient’s long-term observation from 2002 to 2024, during which the patient repeatedly underwent surgical and radiation treatment of tumors of various localizations. The presented clinical case shows the importance of dynamic monitoring and regular examinations by an oncologist, which allows timely verification of a recurrence of the disease or a new malignant neoplasm and achieve the best therapeutic results.
About the Authors
E. V. Semenov
V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Ministry of Health of Russia; A.I. Kryzhanovsky Krasnoyarsk Regional Clinical Cancer Center
Russian Federation
Russian Federation
Eduard Vasilyevich Semenov
1 Partizana Zheleznyaka St., Krasnoyarsk, 660022
16 1st Smolenskaya St., Krasnoyarsk 660133 Russia
N. A. Stepanov
V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
1 Partizana Zheleznyaka St., Krasnoyarsk, 660022
R. A. Zukov
V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Ministry of Health of Russia; A.I. Kryzhanovsky Krasnoyarsk Regional Clinical Cancer Center
Russian Federation
Russian Federation
1 Partizana Zheleznyaka St., Krasnoyarsk 660022
16 1st Smolenskaya St., Krasnoyarsk 660133 Russia
References
1. Vogt A., Schmid S., Heinimann K. et al. Multiple primary tumours: challenges and approaches, a review. ESMO Open 2017;2(2):e000172. DOI: 10.1136/esmoopen-2017-000172
2. Ławniczak M., Gawin A., Jaroszewicz-Heigelmann H. et al. Synchronous and metachronous neoplasms in gastric cancer patients: a 23-year study. World J Gastroenterol 2014;20(23):7480-7. DOI: 10.3748/wjg.v20.i23.7480
3. Bekhtereva S.A., Vazhenin A.V., Domozhirova A.S. Epidemiological aspects of primary multiple breast cancer based on survival analysis. Onkologiya. Zhurnal im. P.A. Gertsena = P.A. Herzen Journal of Oncology 2020;9(2):48-52. (In Russ.). DOI: 10.17116/onkolog2020902148
4. Macq G., Silversmit G., Verdoodt F., Van Eycken L. The epidemiology of multiple primary cancers in Belgium (2004-2017): incidence, proportion, risk, stage and impact on relative survival estimates. BMC Cancer 2023;23(1):349. DOI: 10.1186/s12885-023-10777-7
5. Yang X.B., Zhang L.H., Xue J.N. et al. High incidence combination of multiple primary malignant tumors of the digestive system. World J Gastroenterol 2022;28(41):5982-92. DOI: 10.3748/wjg.v28.i41.5982
6. Grundmann R.T., Meyer F. [Second primary malignancy among cancer survivors - epidemiology, prognosis and clinical relevance (In German)]. Zentralbl Chir 2012;137(6):565-74. DOI: 10.1055/s-0031-1283939
7. Gotay C.C., Ransom S., Pagano I.S. Quality of life in survivors of multiple primary cancers compared with cancer survivor controls. Cancer 2007;110(9):2101-9. DOI: 10.1002/cncr.23005
8. The state of cancer care for the population of Russia in 2022. Ed. by A.D. Kaprin, V.V. Starinskiy, A.O. Shakhzadova Moscow: MNIOI im. PA Gertsena - filial FGBU “NMITs radiologii” Minzdrava Rossii, 2023. 239 p. (In Russ.).
9. Cancer today. Global Cancer Observatory. URL: https://gco.iarc.fr/today/en/dataviz/bars?mode=population (Access date: 08.06.2024).
10. Thomas F., Noon A.P., Rubin N. et al. Comparative outcomes of primary, recurrent, and progressive high-risk non-muscleinvasive bladder cancer. Eur Urol 2013;63(1):145-54. DOI: 10.1016/j.eururo.2012.08.064
11. Alekseev B.Ya., Kaprin A.D., Vorobyev N.V. et al. Observation of multiple primary tumors of the urogenital system. Onkologiya. Zhurnal im. P.A. Gertsena = P.A. Herzen Journal of Oncology. 2013;2(4):63-6. (In Russ.).
12. Catto J.W.F., Gordon K., Collinson M. et al. Radical cystectomy against intravesical BCG for high-risk high-grade nonmuscle invasive bladder cancer: results from the randomized controlled BRAVO-feasibility study. J Clin Oncol 2021;39(3):202-14. DOI: 10.1200/JCO.20.01665
13. Mukeriya, A.F., Zaridze D.G. Lung cancer epidemiology and prevention. Vestnik RONTS im. N.N. Blokhina RAMN = Journal of N.N. Blokhin Russian Cancer Research Center RAMS 2010;21(3):3-13. (In Russ.).
14. Li F., Zhong W.Z., Niu F.Y. et al. Multiple primary malignancies involving lung cancer. BMC Cancer 2015;15:696. DOI: 10.1186/s12885-015-1733-8
15. Liu Y., Kang L., Hao H. et al. Primary synchronous colloid adenocarcinoma and squamous cell carcinoma in the same lung: a rare case report. Medicine (Baltimore) 2021;100(6):e24700. DOI: 10.1097/MD.0000000000024700
16. Cameron M.C., Lee E., Hibler B.P. et al. Basal cell carcinoma: epidemiology; pathophysiology; clinical and histological subtypes; and disease associations. J Am Acad Dermatol 2019;80(2):303-17. DOI: 10.1016/j.jaad.2018.03.060
17. Schottenfeld D. Basal-cell carcinoma of the skin: a harbinger of cutaneous and noncutaneous multiple primary cancer. Ann Intern Med 1996;125(10):852-4. DOI: 10.7326/0003-4819-125-10-199611150-00011
18. Proctor A.E., Thompson L.A., OʼBryant C.L. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma. Ann Pharmacother 2014;48(1):99-106. DOI: 10.1177/1060028013506696
19. Kaatz M., Mohr P., Livingstone E. et al. Effectiveness, safety and utilization of vismodegib for locally advanced basal cell carcinoma under real-world conditions: non-interventional cohort study JONAS. Acta Derm Venereol 2022;102:adv00695. DOI: 10.2340/actadv.v102.293
20. Ascierto P.A., Schadendorf D. Update in the treatment of nonmelanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma. J Immunother Cancer 2022;10(12):e005082. DOI: 10.1136/jitc-2022-005082
21. Chou R., Selph S., Buckley D. et al. Intravesical therapy for the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-analysis. J Urol 2017;197(5):1189-99. DOI: 10.1016/j.juro.2016.12.090
22. Özlem Mermut, Rıza Umar Gürsu. Overview of patients with multiple primary tumors during eighty-four months follow-up: a single center experience. İstanbul Med J 2019;20(4):294-8. DOI: 10.4274/imj.galenos.2019.32815.
Review
For citations:
Semenov E.V., Stepanov N.A., Zukov R.A. A clinical case of a patient with recurrent bladder cancer and primary multiple metachronous tumors. MD-Onco. 2024;4(4):94-99. (In Russ.) https://doi.org/10.17650/2782-3202-2024-4-4-94-99
Views:
102
Email this article 